Observational Study of Lymph Node Metastases in Esophageal Cancer
This study, called the TIGER-study, is looking at how cancer spreads to lymph nodes in people with esophageal cancer (cancer of the tube that connects your throat to your stomach). Researchers want to understand where these metastatic lymph nodes (cancer cells that have spread to lymph nodes) are located after patients have surgery to remove the esophagus (transthoracic esophagectomy). This information helps doctors plan the best surgical treatment. You might be able to join if you have squamous cell or adenocarcinoma of the esophagus or esophago-gastric junction (where the esophagus meets the stomach), and your cancer can be surgically removed. The study aims to follow participants for 5 years to see the distribution of lymph node metastases.
- Study design
- This is a multinational observational study that plans to include 5000 participants. It will follow participants over time to see how their condition progresses.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for approximately 5 years after inclusion in the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Distribution of Lymph Node Metastases in Esophageal Carcinoma
At a glance
Conditions
NCT03222895
Where you'd take part
This study runs at 19 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Amsterdam UMC
Amsterdam, Netherlandsno site contact published
Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Yangpu, Chinano site contact published
Recruiting
Hospital District of Helsinki and Uusimaa
Helsinki, Finlandno site contact published
Recruiting
Hospital Universitario del Mar
Barcelona, Spainno site contact published
Recruiting
Instituto Nacional de Câncer
Rio de Janeiro, Brazilno site contact published
Recruiting
IRCCS Policlinico San Donato
Milan, Italyno site contact published
Recruiting
Karolinska Institutet
Stockholm, Swedenno site contact published
Recruiting
Keio University School of Medicine
Tokyo, Japanno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Suzanne S Gisbertz, MD, PhD · STUDY_CHAIR · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Mark I van Berge Henegouwen, MD, PHD · PRINCIPAL_INVESTIGATOR · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Eliza RC Hagens, MD · STUDY_DIRECTOR · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Distribution of lymph node metastases2 years
The distribution of lymph node metastases in esophageal and esophago-gastric junction carcinoma specimens following transthoracic esophagectomy with at least 2-field lymphadenectomy in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and (disease free) survival.